DNA blood tests may guide better esophageal cancer therapy

NCT ID NCT06792786

First seen Mar 28, 2026 · Last updated May 13, 2026 · Updated 5 times

Summary

This study tests a new approach for people with advanced esophageal cancer that cannot be removed by surgery. Participants first receive a combination of immunotherapy and chemotherapy, followed by standard chemoradiation. Throughout treatment, doctors will monitor tiny bits of tumor DNA in the blood (ctDNA) to see if it can help predict how well the treatment is working. The goal is to improve survival and find better ways to personalize care for this aggressive cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jinhua Municipal Central Hospital

    RECRUITING

    Jinhua, Zhejiang, 321000, China

  • The central Hospital of Lishui City

    RECRUITING

    Lishui, Zhejiang, 323000, China

Conditions

Explore the condition pages connected to this study.